Use of immunomodulators and biologic therapies in children with inflammatory bowel disease

References

• Bousvaros A, Sylvester F, Kugathasan S et al. Challenges in pediatric inflammatory bowel disease. Inflamm. Bowel Dis.12(9), 885–913 (2006).
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Rifas-Shiman SL, Kleinman K et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin. Gastroenterol. Hepatol.5(12), 1424–1429 (2007).
   PubMed Web of Science ®Google Scholar
• Turunen P, Kolho KL, Auvinen A, Iltanen S, Huhtala H, Ashorn M. Incidence of inflammatory bowel disease in Finnish children, 1987–2003. Inflamm. Bowel Dis.12(8), 677–683 (2006).
   PubMed Web of Science ®Google Scholar
• Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol.19(Suppl. A), 5–36 (2005).
   PubMed Web of Science ®Google Scholar
• Bousvaros A, Antonioli DA, Colletti RB et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology Hepatology, and Nutrition and the Crohn’s and Colitis Foundation of America. J. Pediatr. Gastroenterol. Nutr.44(5), 653–674 (2007).
   PubMed Web of Science ®Google Scholar
• Carvalho RS, Abadom V, Dilworth HP, Thompson R, Oliva-Hemker M, Cuffari C. Indeterminate colitis: a significant subgroup of pediatric IBD. Inflamm. Bowel Dis.12(4), 258–262 (2006).
   PubMed Web of Science ®Google Scholar
• Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N. Engl. J. Med.302(18), 981–987 (1980).
   PubMed Web of Science ®Google Scholar
• Belli DC, Seidman E, Bouthillier L et al. Chronic intermittent elemental diet improves growth failure in children with Crohn’s disease. Gastroenterology94(3), 603–610 (1988).
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med.337(15), 1029–1035 (1997).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Panes J, Gomollon F, Taxonera C, Hinojosa J, Clofent J, Nos P. Crohn’s disease: a review of current treatment with a focus on biologics. Drugs67(17), 2511–2537 (2007).
   PubMed Web of Science ®Google Scholar
• Hyams J, Crandall W, Kugathasan S et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology132(3), 863–873; quiz 1165–1166 (2007).
   PubMed Web of Science ®Google Scholar
• Hyams JS, Lerer T, Griffiths A et al. Long-term outcome of maintenance infliximab therapy in children with Crohn’s disease. Inflamm. Bowel Dis.15(6), 816–822 (2009).
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Judd RH, Hoffmann RG et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J. Pediatr.143(4), 525–531 (2003).
   PubMed Web of Science ®Google Scholar
• Van Limbergen J, Russell RK, Drummond HE et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology135(4), 1114–1122 (2008).
   PubMed Web of Science ®Google Scholar
• Ullman T, Odze R, Farraye FA. Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn’s disease of the colon. Inflamm. Bowel Dis.15(4), 630–638 (2009).
   PubMed Web of Science ®Google Scholar
• Hait E, Bousvaros A, Grand R. Pediatric inflammatory bowel disease: what children can teach adults. Inflamm. Bowel Dis.11(6), 519–527 (2005).
   PubMed Web of Science ®Google Scholar
• Heuschkel R, Salvestrini C, Beattie RM, Hildebrand H, Walters T, Griffiths A. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm. Bowel Dis.14(6), 839–849 (2008).
   PubMed Web of Science ®Google Scholar
• Faubion WA Jr, Bousvaros A. Medical therapy for refractory pediatric Crohn’s disease. Clin. Gastroenterol. Hepatol.4(10), 1199–1213 (2006).
   PubMedGoogle Scholar
• Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology119(4), 895–902 (2000).
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Bousvaros A, Hyams J et al. Intercenter variation in initial management of children with Crohn’s disease. Inflamm. Bowel Dis.13(7), 890–895 (2007).
   PubMed Web of Science ®Google Scholar
• Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin. Gastroenterol. Hepatol.2(9), 731–743 (2004).
   PubMed Web of Science ®Google Scholar
• Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology115(4), 813–821 (1998).
   PubMed Web of Science ®Google Scholar
• Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut54(8), 1121–1125 (2005).
   PubMed Web of Science ®Google Scholar
• Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol. Rev.57(2), 163–172 (2005).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Alfadhli A. Methotrexate in inflammatory bowel disease. Gastroenterol. Clin. North Am.33(2), 407–420, xi (2004).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rochon J, Fedorak RN et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N. Engl. J. Med.332(5), 292–297 (1995).
   PubMed Web of Science ®Google Scholar
• Uhlen S, Belbouab R, Narebski K et al. Efficacy of methotrexate in pediatric Crohn’s disease: a French multicenter study. Inflamm. Bowel Dis.12(11), 1053–1057 (2006).
   PubMed Web of Science ®Google Scholar
• Turner D, Grossman AB, Rosh J et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn’s disease. Am. J. Gastroenterol.102(12), 2804–2812 (2007).
   PubMed Web of Science ®Google Scholar
• Stephens MC, Baldassano RN, York A et al. The bioavailability of oral methotrexate in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr.40(4), 445–449 (2005).
   PubMed Web of Science ®Google Scholar
• Papa A, Mocci G, Bonizzi M et al. Use of infliximab in particular clinical settings: management based on current evidence. Am. J. Gastroenterol.104(6), 1575–1586 (2009).
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med.340(18), 1398–1405 (1999).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med.353(23), 2462–2476 (2005).
   PubMed Web of Science ®Google Scholar
• Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn’s disease. Inflamm. Bowel Dis.13(4), 424–430 (2007).
   PubMed Web of Science ®Google Scholar
• Shamir R, Phillip M, Levine A. Growth retardation in pediatric Crohn’s disease: pathogenesis and interventions. Inflamm. Bowel Dis.13(5), 620–628 (2007).
   PubMed Web of Science ®Google Scholar
• Ahmed TA, Buzzelli MD, Lang CH et al. Interleukin-6 inhibits growth hormone-mediated gene expression in hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol.292(6), G1793–G1803 (2007).
   Web of Science ®Google Scholar
• DiFedele LM, He J, Bonkowski EL et al. Tumor necrosis factor a blockade restores growth hormone signaling in murine colitis. Gastroenterology128(5), 1278–1291 (2005).
   PubMed Web of Science ®Google Scholar
• Bousvaros A, Kirschner BS, Werlin SL et al. Oral tacrolimus treatment of severe colitis in children. J. Pediatr.137(6), 794–799 (2000).
   PubMed Web of Science ®Google Scholar
• Ramakrishna J, Langhans N, Calenda K, Grand RJ, Verhave M. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr.22(3), 296–302 (1996).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Feagan BG et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology137(4), 1250–1260; quiz 1520 (2009).
   PubMed Web of Science ®Google Scholar
• Hyams JS, Lerer T, Griffiths A et al. Outcome following infliximab therapy in children with ulcerative colitis. Am. J. Gastroenterol.105(6), 1430–1436 (2010).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn’s disease: results from the CHARM trial. Am. J. Gastroenterol.104(5), 1170–1179 (2009).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut56(9), 1232–1239 (2007).
   PubMed Web of Science ®Google Scholar
• Viola F, Civitelli F, Di Nardo G et al. Efficacy of adalimumab in moderate-to-severe pediatric Crohn’s disease. Am. J. Gastroenterol.104(10), 2566–2571 (2009).
   PubMed Web of Science ®Google Scholar
• Rosh JR, Lerer T, Markowitz J et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn’s disease. Am. J. Gastroenterol.104(12), 3042–3049 (2009).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn’s disease. N. Engl. J. Med.357(3), 228–238 (2007).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med.357(3), 239–250 (2007).
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Levy MB, Saeian K et al. Infliximab retreatment in adults and children with Crohn’s disease: risk factors for the development of delayed severe systemic reaction. Am. J. Gastroenterol.97(6), 1408–1414 (2002).
   PubMed Web of Science ®Google Scholar
• Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment. Pharmacol. Ther.17(1), 75–84 (2003).
   PubMed Web of Science ®Google Scholar
• Puchner TC, Kugathasan S, Kelly KJ, Binion DG. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn’s disease patients with prior anaphylactic reaction. Inflamm. Bowel Dis.7(1), 34–37 (2001).
   PubMed Web of Science ®Google Scholar
• Mutlu GM, Mutlu EA, Bellmeyer A, Rubinstein I. Pulmonary adverse events of anti-tumor necrosis factor-a antibody therapy. Am. J. Med.119(8), 639–646 (2006).
   PubMed Web of Science ®Google Scholar
• Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin. Gastroenterol. Hepatol.2(4), 309–313 (2004).
   PubMed Web of Science ®Google Scholar
• Jain VV, Evans T, Peterson MW. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor a in a patient from a nonendemic area. Respir. Med.100(7), 1291–1293 (2006).
   PubMed Web of Science ®Google Scholar
• Dweik M, Baethge BA, Duarte AG. Coccidioidomycosis pneumonia in a nonendemic area associated with infliximab. South. Med. J.100(5), 517–518 (2007).
   PubMedGoogle Scholar
• Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm. Bowel Dis.13(8), 1024–1030 (2007).
   PubMed Web of Science ®Google Scholar
• Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J. Pediatr. Gastroenterol. Nutr.48(3), 386–388 (2009).
   PubMed Web of Science ®Google Scholar
• D’Haens GR. Top-down therapy for Crohn’s disease: rationale and evidence. Acta. Clin. Belg.64(6), 540–546 (2009).
   PubMed Web of Science ®Google Scholar
• Davis SL, Perri MB, Donabedian SM et al. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J. Clin. Microbiol.45(6), 1705–1711 (2007).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Hass S, Niecko T, White J. Health-related quality of life during natalizumab maintenance therapy for Crohn’s disease. Am. J. Gastroenterol.102(12), 2737–2746 (2007).
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology132(5), 1672–1683 (2007).
   PubMed Web of Science ®Google Scholar
• Hyams JS, Wilson DC, Thomas A et al. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J. Pediatr. Gastroenterol. Nutr.44(2), 185–191 (2007).
   PubMed Web of Science ®Google Scholar
• Clifford DB. Natalizumab and PML: a risky business? Gut57(10), 1347–1349 (2008).
   PubMed Web of Science ®Google Scholar